{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:30:12Z","timestamp":1791412212591,"version":"4.3.3"},"reference-count":106,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vaccine.2024.01.044","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T07:24:14Z","timestamp":1716535454000},"page":"S82-S100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S1","title":["Vaccine value profile for herpes simplex virus"],"prefix":"10.1016","volume":"42","author":[{"given":"Christine","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Scheele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Boily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Delany-Moretlwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Looker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve B.","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ndowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2024.01.044_b0005","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMcp1603178","article-title":"Genital herpes","volume":"375","author":"Gnann","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.044_b0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.044_b0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","article-title":"Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data","volume":"20","author":"Looker","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/QAI.0000000000002743","article-title":"What is the burden of heterosexually acquired HIV due to HSV-2? global and regional model-based estimates of the proportion and number of HIV infections attributable to HSV-2 infection","volume":"88","author":"Silhol","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"26","key":"10.1016\/j.vaccine.2024.01.044_b0025","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.044_b0030","unstructured":"World Health Organization. Global health sector strategies 2022-2030. 2023 [cited 2023 05 March]; Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/strategies\/global-health-sector-strategies."},{"key":"10.1016\/j.vaccine.2024.01.044_b0035","unstructured":"World Health Organization, WHO preferred product characteristics for herpes simplex virus vaccines. 2019, World Health Organization: Geneva. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241515580."},{"issue":"9605","key":"10.1016\/j.vaccine.2024.01.044_b0040","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","article-title":"Genital herpes","volume":"370","author":"Gupta","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.01.044_b0045","article-title":"Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression","volume":"12","author":"AlMukdad","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2024.01.044_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100876","article-title":"Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions","volume":"35","author":"Harfouche","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.044_b0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/sextrans-2021-054972","article-title":"Epidemiology of herpes simplex virus type 2 in Latin America and the Caribbean: systematic review, meta-analyses and metaregressions","volume":"97","author":"Harfouche","year":"2021","journal-title":"Sex Transm Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0060","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/S2214-109X(16)30362-X","article-title":"First estimates of the global and regional incidence of neonatal herpes infection","volume":"5","author":"Looker","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/jpids\/piab105","article-title":"Neonatal herpes simplex virus infection: Epidemiology and outcomes in the modern era","volume":"11","author":"Melvin","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idnow.2021.11.007","article-title":"Changing profile of encephalitis: Results of a 4-year study in France","volume":"52","author":"Mailles","year":"2022","journal-title":"Infect Dis Now"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.044_b0075","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/cid\/cis226","article-title":"Long-term outcome of patients presenting with acute infectious encephalitis of various causes in France","volume":"54","author":"Mailles","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0080","doi-asserted-by":"crossref","first-page":"e001875","DOI":"10.1136\/bmjgh-2019-001875","article-title":"The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study","volume":"5","author":"Looker","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.044_b0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clp.2021.03.003","article-title":"Neonatal Herpes Simplex Virus Disease: Updates and Continued Challenges","volume":"48","author":"Samies","year":"2021","journal-title":"Clin Perinatol"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.044_b0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09286586.2021.1962919","article-title":"Incidence of herpes simplex virus keratitis and other ocular disease: Global review and estimates","volume":"29","author":"McCormick","year":"2022","journal-title":"Ophthalmic Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.044_b0095","article-title":"Overwhelming evidence for a major role for herpes simplex virus type 1 (HSV1) in alzheimer's disease (AD); Underwhelming evidence against","volume":"9","author":"Itzhaki","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.044_b0100","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QCO.0000000000000889","article-title":"Resistant herpes simplex virus infections - who, when, and what's new?","volume":"35","author":"Kotton","year":"2022","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.044_b0105","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/01.WNL.0000134652.51657.10","article-title":"HSV-2 sacral radiculitis (Elsberg syndrome)","volume":"63","author":"Eberhardt","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2024.01.044_b0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fneur.2017.00199","article-title":"Herpes simplex virus type 2 Myelitis: Case report and review of the literature","volume":"8","author":"Nardone","year":"2017","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.044_b0115","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1258\/0956462011923859","article-title":"Patients' perspectives on the burden of recurrent genital herpes","volume":"12","author":"Patel","year":"2001","journal-title":"Int J STD AIDS"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.044_b0120","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.11124\/JBIES-21-00057","article-title":"Impact of primary and recurrent genital herpes on the quality of life of young people and adults: a mixed methods systematic review","volume":"20","author":"Bennett","year":"2022","journal-title":"JBI Evid Synth"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12916-019-1285-x","article-title":"Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions","volume":"17","author":"Ayoub","year":"2019","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.044_b0130","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/cid\/ciy943","article-title":"Herpes simplex virus type 1 genital ulcer disease at a tertiary care hospital in north india","volume":"68","author":"Brijwal","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.044_b0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/jama.289.2.203","article-title":"Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant","volume":"289","author":"Brown","year":"2003","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.044_b0140","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jpeds.2007.04.065","article-title":"Seroprevalence of herpes simplex virus type 1 in children in the United States","volume":"151","author":"Xu","year":"2007","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.044_b0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/sti.2004.012039","article-title":"A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2","volume":"81","author":"Looker","year":"2005","journal-title":"Sex Transm Infect"},{"issue":"19","key":"10.1016\/j.vaccine.2024.01.044_b0150","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM199911043411904","article-title":"A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group","volume":"341","author":"Langenberg","year":"1999","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.044_b0155","doi-asserted-by":"crossref","first-page":"e1002475","DOI":"10.1371\/journal.pmed.1002475","article-title":"Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study","volume":"14","author":"Johnston","year":"2017","journal-title":"PLoS Med"},{"issue":"16","key":"10.1016\/j.vaccine.2024.01.044_b0160","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1128\/JVI.01302-15","article-title":"Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins","volume":"89","author":"Lamers","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.01.044_b0165","doi-asserted-by":"crossref","first-page":"44084","DOI":"10.1038\/srep44084","article-title":"Worldwide circulation of HSV-2 \u00d7 HSV-1 recombinant strains","volume":"7","author":"Koelle","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.044_b0170","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/infdis\/jir047","article-title":"Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa","volume":"203","author":"Dudek","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.044_b0175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.virol.2013.12.014","article-title":"Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain","volume":"450\u2013451","author":"Colgrove","year":"2014","journal-title":"Virology"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2024.01.044_b0180","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1086\/425271","article-title":"Role of herd immunity in determining the effect of vaccines against sexually transmitted disease","volume":"191","author":"Garnett","year":"2005","journal-title":"J Infect Dis"},{"issue":"50","key":"10.1016\/j.vaccine.2024.01.044_b0185","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1016\/j.vaccine.2018.02.067","article-title":"Review of mathematical models of HSV-2 vaccination: Implications for vaccine development","volume":"37","author":"Spicknall","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.044_b0190","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1473-3099(17)30405-X","article-title":"Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis","volume":"17","author":"Looker","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"9263","key":"10.1016\/j.vaccine.2024.01.044_b0195","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(00)04331-2","article-title":"Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai","volume":"357","author":"Gray","year":"2001","journal-title":"Uganda Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0200","doi-asserted-by":"crossref","first-page":"e59037","DOI":"10.1371\/journal.pone.0059037","article-title":"Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania","volume":"8","author":"Todd","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vaccine.2024.01.044_b0205","doi-asserted-by":"crossref","first-page":"845","DOI":"10.7326\/0003-4819-123-11-199512010-00006","article-title":"Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women","volume":"123","author":"Augenbraun","year":"1995","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.280.1.61","article-title":"Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men","volume":"280","author":"Schacker","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2024.01.044_b0215","doi-asserted-by":"crossref","unstructured":"Chaiyakunapruk, N., et al., Estimated global and regional economic burden of genital herpes simplex virus infection among 15-49 year-olds in 2016. BMC Glob Public Health 2024; in press.","DOI":"10.1186\/s44263-024-00053-6"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.044_b0220","doi-asserted-by":"crossref","first-page":"e1003938","DOI":"10.1371\/journal.pmed.1003938","article-title":"Estimated economic burden of genital herpes and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income countries: A modeling study","volume":"19","author":"Silva","year":"2022","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.044_b0225","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/OLQ.0000000000000689","article-title":"Performance of commercial enzyme-linked immunoassays for diagnosis of herpes simplex virus-1 and herpes simplex virus-2 infection in a clinical setting","volume":"44","author":"Agyemang","year":"2017","journal-title":"Sex Transm Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2024.01.044_b0230","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.vaccine.2015.12.076","article-title":"Status of vaccine research and development of vaccines for herpes simplex virus","volume":"34","author":"Johnston","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.044_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually Transmitted Infections Treatment Guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/515385","article-title":"Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group","volume":"178","author":"Reitano","year":"1998","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0245","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00007435-200303000-00010","article-title":"Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study","volume":"30","author":"Romanowski","year":"2003","journal-title":"Sex Transm Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.044_b0250","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.olq.0000237853.69443.71","article-title":"A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir","volume":"34","author":"Fife","year":"2007","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.044_b0260","doi-asserted-by":"crossref","first-page":"p. ofac494","DOI":"10.1093\/ofid\/ofac494","article-title":"Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study","volume":"9","author":"Kawashima","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2024.01.044_b0265","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/archinternmed.2009.177","article-title":"A pooled analysis of the effect of condoms in preventing HSV-2 acquisition","volume":"169","author":"Martin","year":"2009","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.044_b0270","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/OLQ.0b013e318248aa8a","article-title":"Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition","volume":"39","author":"Stanaway","year":"2012","journal-title":"Sex Transm Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2024.01.044_b0275","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa0802556","article-title":"Male circumcision for the prevention of HSV-2 and HPV infections and syphilis","volume":"360","author":"Tobian","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0280","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.AOG.0000219749.96274.15","article-title":"Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial","volume":"108","author":"Sheffield","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"9630","key":"10.1016\/j.vaccine.2024.01.044_b0285","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/S0140-6736(08)60920-4","article-title":"Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial","volume":"371","author":"Celum","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.044_b0290","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa0904849","article-title":"Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2","volume":"362","author":"Celum","year":"2010","journal-title":"N Engl J Med"},{"issue":"50","key":"10.1016\/j.vaccine.2024.01.044_b0295","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1016\/j.vaccine.2017.03.074","article-title":"Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling","volume":"37","author":"Gottlieb","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.044_b0300","unstructured":"Child Health and Development, et al., The Global Strategy for Women's, Children's, and Adolescents' Health (2016-2030), World Health Organization, Editor. 2018."},{"key":"10.1016\/j.vaccine.2024.01.044_b0305","unstructured":"World Health Organization, Global health sector strategy on Sexually Transmitted Infections, 2016-2021: towards ending STIs, World Health Organization, Editor. 2016. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-RHR-16.09."},{"key":"10.1016\/j.vaccine.2024.01.044_b0310","unstructured":"World Health Organization, Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/strategies\/global-health-sector-strategies."},{"issue":"14","key":"10.1016\/j.vaccine.2024.01.044_b0315","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2014.01.053","article-title":"Vaccines against sexually transmitted infections: the way forward","volume":"32","author":"Broutet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.044_b0320","unstructured":"World Health Organization, Immunization Agenda 2030: a global strategy to leave no one behind. Available from: https:\/\/www.immunizationagenda2030.org\/."},{"key":"10.1016\/j.vaccine.2024.01.044_b0325","unstructured":"NIAID. Join NIAID staff workshop on genital herpes. [cited 2023 March 16]; Available from: https:\/\/www.niaid.nih.gov\/grants-contracts\/join-niaid-staff-workshop-genital-herpes."},{"key":"10.1016\/j.vaccine.2024.01.044_b0330","unstructured":"National Institutes of Health. Strategic plan for herpes simplex virus research (2023-2028), NIH 2023. Available from: https:\/\/www.niaid.nih.gov\/sites\/default\/files\/nih-herpes-simplex-strategic-plan-2023.pdf."},{"issue":"23","key":"10.1016\/j.vaccine.2024.01.044_b0335","doi-asserted-by":"crossref","first-page":"14632","DOI":"10.1128\/JVI.79.23.14632-14639.2005","article-title":"The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies","volume":"79","author":"Yim","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.044_b0340","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01574-18","article-title":"Acute infection and subsequent subclinical reactivation of herpes simplex virus 2 after vaginal inoculation of rhesus macaques","volume":"93","author":"Lo","year":"2019","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.044_b0345","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1002\/cpz1.332","article-title":"Guinea pig and mouse models for genital herpes infection","volume":"1","author":"Hook","year":"2021","journal-title":"Curr Protoc"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.044_b0350","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1172\/JCI1758","article-title":"Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes","volume":"101","author":"Koelle","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2024.01.044_b0355","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fimmu.2019.00373","article-title":"Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design","volume":"10","author":"Truong","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2024.01.044_b0360","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142088","article-title":"B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin","volume":"131","author":"Ford","year":"2021","journal-title":"J Clin Invest"},{"issue":"7450","key":"10.1016\/j.vaccine.2024.01.044_b0365","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nature12110","article-title":"Immune surveillance by CD8 \u03b1\u03b1 + skin-resident T cells in human herpes virus infection","volume":"497","author":"Zhu","year":"2013","journal-title":"Nature"},{"issue":"7424","key":"10.1016\/j.vaccine.2024.01.044_b0370","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature11522","article-title":"A vaccine strategy that protects against genital herpes by establishing local memory T cells","volume":"491","author":"Shin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.01.044_b0375","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41541-019-0129-1","article-title":"Successful application of prime and pull strategy for a therapeutic HSV vaccine","volume":"4","author":"Bernstein","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2024.01.044_b0380","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/infdis\/jix088","article-title":"Distinct Effects of the Cervicovaginal Microbiota and Herpes Simplex Type 2 Infection on Female Genital Tract Immunology","volume":"215","author":"Shannon","year":"2017","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2024.01.044_b0385","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/infdis\/jiy372","article-title":"Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals","volume":"218","author":"Agyemang","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0390","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/infdis\/jiv451","article-title":"Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda","volume":"213","author":"Phipps","year":"2016","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2024.01.044_b0395","doi-asserted-by":"crossref","first-page":"e0163541","DOI":"10.1371\/journal.pone.0163541","article-title":"Genital HSV Shedding among Kenyan Women Initiating Antiretroviral Therapy","volume":"11","author":"Manguro","year":"2016","journal-title":"PLoS One"},{"issue":"95","key":"10.1016\/j.vaccine.2024.01.044_b0400","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2014.0160","article-title":"Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding","volume":"11","author":"Schiffer","year":"2014","journal-title":"J R Soc Interface"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.044_b0405","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3855\/jidc.11599","article-title":"Herpes Simplex virus type 2 seroprevalence and risk factors among adolescents and youth with HIV-1 in Northern","volume":"14","author":"Madebe","year":"2020","journal-title":"Tanzania J Infect Dev Ctries"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0410","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.044_b0415","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/infdis\/jit651","article-title":"Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women","volume":"209","author":"Belshe","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.044_b0420","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiz225","article-title":"A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection","volume":"220","author":"Dropulic","year":"2019","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.044_b0425","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jix004","article-title":"therapeutic vaccine for genital herpes simplex Virus-2 Infection: Findings from a randomized trial","volume":"215","author":"Bernstein","year":"2017","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.044_b0430","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiy415","article-title":"Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex Virus-2, on Viral shedding and lesions: results of a randomized placebo-controlled trial","volume":"218","author":"Van Wagoner","year":"2018","journal-title":"J Infect Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2024.01.044_b0435","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.vaccine.2019.05.009","article-title":"Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.044_b0440","doi-asserted-by":"crossref","first-page":"e0226320","DOI":"10.1371\/journal.pone.0226320","article-title":"Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I\/IIa trial","volume":"14","author":"Chandra","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.01.044_b0445","first-page":"1","article-title":"Prevalence of herpes simplex virus Type 1 and Type 2 in Persons Aged 14\u201349: United States, 2015\u20132016","volume":"304","author":"McQuillan","year":"2018","journal-title":"NCHS Data Brief"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.044_b0450","doi-asserted-by":"crossref","DOI":"10.3390\/v13081637","article-title":"Rational design of live-attenuated vaccines against herpes simplex viruses","volume":"13","author":"Stanfield","year":"2021","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.044_b0455","first-page":"754","article-title":"A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2","volume":"217","author":"Burn","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0460","doi-asserted-by":"crossref","first-page":"e17748","DOI":"10.1371\/journal.pone.0017748","article-title":"A Live-Attenuated HSV-2 ICP0- Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine","volume":"6","author":"Halford","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0465","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-020-00254-8","article-title":"The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model","volume":"5","author":"Bernstein","year":"2020","journal-title":"npj Vaccines"},{"issue":"43","key":"10.1016\/j.vaccine.2024.01.044_b0470","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1016\/j.vaccine.2019.08.077","article-title":"Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0475","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41385-019-0131-y","article-title":"Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection","volume":"12","author":"Royer","year":"2019","journal-title":"Mucosal Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.044_b0480","doi-asserted-by":"crossref","first-page":"e04368","DOI":"10.1016\/j.heliyon.2020.e04368","article-title":"Dynamics of HSV-2 infection with a therapeutic vaccine","volume":"6","author":"Venturino","year":"2020","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.044_b0485","article-title":"Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses","volume":"8","author":"Ayoub","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.01.044_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104530","article-title":"The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study","volume":"90","author":"Stone","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.044_b0495","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12955-022-01934-w","article-title":"Health-related quality of life in individuals with genital herpes: a systematic review","volume":"20","author":"Devine","year":"2022","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.044_b0500","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/OLQ.0b013e3181e212e5","article-title":"Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries","volume":"37","author":"Corbell","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.044_b0505","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/OLQ.0b013e3181d3d023","article-title":"Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2","volume":"37","author":"Alsallaq","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.044_b0510","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.vaccine.2008.11.074","article-title":"Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa","volume":"27","author":"Freeman","year":"2009","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2024.01.044_b0515","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1016\/j.vaccine.2017.10.084","article-title":"Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017","volume":"37","author":"Gottlieb","year":"2019","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.044_b0520","doi-asserted-by":"crossref","first-page":"e0160707","DOI":"10.1371\/journal.pone.0160707","article-title":"Assessment of the broader economic consequences of HPV prevention from a government-perspective: A fiscal analytic approach","volume":"11","author":"Setiawan","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vaccine.2024.01.044_b0525","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-003006","article-title":"Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries","volume":"5","author":"Ochalek","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"13","key":"10.1016\/j.vaccine.2024.01.044_b0530","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/cncr.30007","article-title":"Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines","volume":"122","author":"Burger","year":"2016","journal-title":"Cancer"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T13:51:16Z","timestamp":1728049876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":106,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0264410X24000550"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine value profile for herpes simplex virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}